scholarly journals REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics

2021 ◽  
Author(s):  
Mohamed A. Kamal ◽  
Robert Dingman ◽  
Claire Q. Wang ◽  
Ching‐Ha Lai ◽  
Manoj Rajadhyaksha ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Fel D 1

Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis

2015 ◽  
Vol 54 (11) ◽  
pp. 1107-1123 ◽  
Author(s):  
David Ternant ◽  
Theodora Bejan-Angoulvant ◽  
Christophe Passot ◽  
Denis Mulleman ◽  
Gilles Paintaud
Keyword(s):  
Rheumatoid Arthritis ◽  
Monoclonal Antibodies ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Clinical Pharmacokinetics

scholarly journals Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies

mAbs ◽  
2012 ◽  
Vol 4 (6) ◽  
pp. 724-731 ◽  
Author(s):  
Deborah L. Mortensen ◽  
Saileta Prabhu ◽  
Eric G. Stefanich ◽  
Saloumeh Kadkhodayan-Fischer ◽  
Thomas R. Gelzleichter ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Binding Affinity ◽  
Effector Function ◽  
Antigen Binding ◽  
Pharmacokinetics And Pharmacodynamics

scholarly journals Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment

2019 ◽  
Vol 15 (2) ◽  
pp. 113-120 ◽  
Author(s):  
Diego Bagnasco ◽  
Enrico Heffler ◽  
Elisa Testino ◽  
Giovanni Passalacqua ◽  
Giorgio Walter Canonica
Keyword(s):  
Monoclonal Antibodies ◽  
Asthma Treatment ◽  
Pharmacokinetics And Pharmacodynamics

scholarly journals Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies

Pharmaceutics ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 1180
Author(s):  
Danuta Szkutnik-Fiedler
Keyword(s):  
Monoclonal Antibodies ◽  
Drug Interactions ◽  
New Drugs ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Glycoprotein P ◽  
P Glycoprotein ◽  
Calcitonin Gene ◽  
The Us ◽  
Cyp3a4 Inhibitors ◽  
Serotonergic Drugs

In the last few years, there have been significant advances in migraine management and prevention. Lasmiditan, ubrogepant, rimegepant and monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) are new drugs that were launched on the US pharmaceutical market; some of them also in Europe. This publication reviews the available worldwide references on the safety of these anti-migraine drugs with a focus on the possible drug–drug (DDI) or drug–food interactions. As is known, bioavailability of a drug and, hence, its pharmacological efficacy depend on its pharmacokinetics and pharmacodynamics, which may be altered by drug interactions. This paper discusses the interactions of gepants and lasmiditan with, i.a., serotonergic drugs, CYP3A4 inhibitors, and inducers or breast cancer resistant protein (BCRP) and P-glycoprotein (P-gp) inhibitors. In the case of monoclonal antibodies, the issue of pharmacodynamic interactions related to the modulation of the immune system functions was addressed. It also focuses on the effect of monoclonal antibodies on expression of class Fc gamma receptors (FcγR).

Bottom-up sample preparation for the LC–MS/MS quantification of anti-cancer monoclonal antibodies in bio matrices

Bioanalysis ◽  
2020 ◽  
Vol 12 (19) ◽  
pp. 1405-1425
Author(s):  
Karen AM de Jong ◽  
Suse J van Breugel ◽  
Michel JX Hillebrand ◽  
Hilde Rosing ◽  
Alwin DR Huitema ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Internal Standard ◽  
Binding Assays ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Top Down ◽  
High Demand ◽  
Bottom Up ◽  
Signature Peptide ◽  
Anti Cancer ◽  
Therapeutic Monoclonal Antibodies

Therapeutic monoclonal antibodies (mAbs) are rapidly taking over the treatment of many malignancies, and an astonishing number of mAbs is in development. This causes a high demand for quantification of mAbs in biomatrices both for measuring therapeutic mAb concentrations and to support pharmacokinetics and pharmacodynamics studies. Conventionally, ligand-binding assays are used for these purposes, but LC–MS is gaining popularity. Although intact (top-down) and subunit (middle-down) mAb quantification is reported, signature peptide (bottom-up) quantification is currently most advantageous. This review provides an overview of the reported bottom-up mAb quantification methods in biomatrices as well as general recommendations regarding signature peptide and internal standard selection, reagent use and optimization of digestion in bottom-up quantification methods.

Sign in / Sign up

Export Citation Format

Share Document